In 2021, ASCO announced the latest data of 70 patients with HER2+ BC and 48 patients with HER2-low expression BC, the trial results show that RC48 can achieve good efficacy in both HER2+ and low-expression BC patients, and there are no new safety problems, while the 2.0 mg/Kg dose group had the best benefit-to-risk ratio, with m-PFS of 6.3 months. Here, ERBB2 is linked to breast cancer.